Unknown

Dataset Information

0

Inactivated rabies-based Lassa fever virus vaccine candidate LASSARAB protects nonhuman primates from lethal disease.


ABSTRACT: Lassa fever virus (LASV), a member of the Arenavirus family, is the etiological agent of Lassa fever, a severe hemorrhagic disease that causes considerable morbidity and mortality in the endemic areas of West Africa. LASV is a rodent-borne CDC Tier One biological threat agent and is on the World Health Organization's (WHO) Priority Pathogen list. Currently, no FDA-licensed vaccines or specific therapeutics are available. Here, we describe the efficacy of a deactivated rabies virus (RABV)-based vaccine encoding the glycoprotein precursor (GPC) of LASV (LASSARAB). Nonhuman primates (NHPs) were administered a two-dose regimen of LASSARAB or an irrelevant RABV-based vaccine to serve as a negative control. NHPs immunized with LASSARAB developed strong humoral responses to LASV-GPC. Upon challenge, NHPs vaccinated with LASSARAB survived to the study endpoint, whereas NHPs in the control group did not. This study demonstrates that LASSARAB is a worthy candidate for continued development.

SUBMITTER: Scher G 

PROVIDER: S-EPMC11315998 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Inactivated rabies-based Lassa fever virus vaccine candidate LASSARAB protects nonhuman primates from lethal disease.

Scher Gabrielle G   Yankowski Catherine C   Kurup Drishya D   Josleyn Nicole M NM   Wilkinson Eric R ER   Wells Jay J   Steffens Jesse J   Lynn Ginger G   Vantongeren Sean S   Zeng Xiankun X   Twenhafel Nancy N   Cashman Kathleen A KA   Schnell Matthias J MJ  

NPJ vaccines 20240809 1


Lassa fever virus (LASV), a member of the Arenavirus family, is the etiological agent of Lassa fever, a severe hemorrhagic disease that causes considerable morbidity and mortality in the endemic areas of West Africa. LASV is a rodent-borne CDC Tier One biological threat agent and is on the World Health Organization's (WHO) Priority Pathogen list. Currently, no FDA-licensed vaccines or specific therapeutics are available. Here, we describe the efficacy of a deactivated rabies virus (RABV)-based v  ...[more]

Similar Datasets

| S-EPMC8448432 | biostudies-literature
| S-EPMC5719877 | biostudies-literature
| S-EPMC387704 | biostudies-literature
| S-EPMC6934204 | biostudies-literature
| S-EPMC8944267 | biostudies-literature
| S-EPMC9182267 | biostudies-literature
| S-EPMC10897540 | biostudies-literature
| S-EPMC3667758 | biostudies-literature
| S-EPMC7925663 | biostudies-literature
| S-EPMC6181965 | biostudies-literature